According to international diabetes news, Lexicon Pharmaceuticals said that their experimental diabetes drug has hit all the main goals of its mid-stage trial. The news sent Lexicon shares soaring considerably during morning trade.
The drug, LX4211, reportedly showed an improvement in glycaemic control. The tests were statistically significant. Stephen Willey, an analyst, was reported in diabetes news as commenting: "Today's results lay down the foundation for partnership talks ... the primary care diabetes market is a huge opportunity for the company and they will have to partner the drug to send it across the finish line."
The study involved some 36 patients with type 2 diabetes . The senior vice president of clinical development at Lexicon, Philip Brown, reportedly commented: "The primary objective of the study was to verify the safety and tolerability of the drug, which we clearly met while the primary endpoint of the study was to show increase in 24-hour urinary glucose excretion."
Lexicon diabetes drug hits mid-stage trial
Thu, 21 Jan 2010
Recommended links
Diabetes based financial servicesDiabetes book reviews
Diabetes myLifestyle
Diabetes donate
Diabetes pensions and annuities
Diabetes.co.uk ID alert wristband
The Diet Plate to help control diabetes
Diabetes drug clinical trials underway
Death risk increased 60 per cent by diabetes drug
Roche diabetes drug hits targets
New type 1 diabetes drug
Diabetes drug warning has doctors on alert
Label change for type 2 diabetes drug
Diabetes prevention using diet, not drugs
Diabetes drug better for weight loss
Diabetes drug may have pancreatitis risk
Denial over diabetes drug link
Heart risk not alleviated by diabetes drugs
Obesity increases diabetes drug bill
Med diet could delay diabetes drugs
Diabetes drug prescriptions must stop, study says
Stop prescribing diabetes drug, scientists say
New diabetes drug same price
Dementia drug risk amongst people with diabetes
Iron binding drug could help diabetes neuropathy
Diabetes drug cleared of cancer risk
Canada reviews diabetes drug
Diabetes drug review causes share climb
Sanofi maintain diabetes drug no riskier than insulin
Diabetes drug cleared for European market
Drug association encourages use of diabetes drug
Diabetes drug requires more research, FDA rule
